DiaMedica Therapeutics Inc.
DMAC
$3.85
$0.205.48%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -3.27% | -6.53% | 2.04% | 7.39% | 27.93% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 35.36% | 25.46% | 24.33% | 28.92% | 34.41% |
Operating Income | -35.36% | -25.46% | -24.33% | -28.92% | -34.41% |
Income Before Tax | -40.35% | -26.25% | -20.73% | -20.13% | -24.69% |
Income Tax Expenses | -32.56% | -30.23% | 53.57% | 53.57% | 53.57% |
Earnings from Continuing Operations | -40.19% | -26.12% | -20.78% | -20.19% | -24.74% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -40.19% | -26.12% | -20.78% | -20.19% | -24.74% |
EBIT | -35.36% | -25.46% | -24.33% | -28.92% | -34.41% |
EBITDA | -35.36% | -25.45% | -24.32% | -28.92% | -34.44% |
EPS Basic | -16.74% | 2.46% | 11.25% | 15.63% | 5.26% |
Normalized Basic EPS | -16.81% | 2.42% | 11.32% | 15.67% | 5.27% |
EPS Diluted | -16.74% | 2.46% | 11.25% | 15.63% | 5.26% |
Normalized Diluted EPS | -16.81% | 2.42% | 11.32% | 15.67% | 5.27% |
Average Basic Shares Outstanding | 17.87% | 24.56% | 32.70% | 42.52% | 33.52% |
Average Diluted Shares Outstanding | 17.87% | 24.56% | 32.70% | 42.52% | 33.52% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |